TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05824169: A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Sponsor: GeneCradle Inc · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,616,850

Rescue Site Savings

+$5,034,125

Unlock Full NCT05824169 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05824169 Rescue Dossier →